Waiving patent protection for COVID-19 vaccines does not solve problems

The research-based pharmaceutical companies oppose the waiving of patent protection because research would be hindered and the problem of the still lacking production capacities would be exacerbated.

Eine Forscherin arbeitet in einer Laborumgebung vor einem Monitor.

Illustration des Zusammenspiels von Nationen, COVAX Facility und Impfstoffherstellern

Downloads: PNG | JPG | PDF
Graphic is released for reporting with indication "Figure: vfa" without costs; no use for promotional material.

This text originally appeared as a guest article by vfa President Han Steutel in the magazine "UNITED NATIONS".